Managing diabetes in Asia: Overcoming obstacles and the role of DPP-IV inhibitors

Diabetes Research and Clinical Practice

Volumn 95, Issue 2, 2012, Pages 179-188

  Mu, Yi Ming ^a   Misra, Anoop ^b   Adam, John M F ^c   Chan, Siew Pheng ^d   Chow, Francis C C ^e   Cunanan, Elaine Cheeay ^f   Deerochanawong, Chaicharn ^g   Jang, Hak Chul ^h   Khue, Nguyen Thy ⁱ   Sheu, Wayne H H ^j   Tan, Kevin E K ^k  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b FORTIS HOSPITAL   (India)

^c Dr Wahidin Sudirohusodo Hospital   (Indonesia)

^d UNIVERSITY OF MALAYA   (Malaysia)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f UNIVERSITY OF SANTO TOMAS HOSPITAL   (Philippines)

^g RAJAVITHI HOSPITAL   (Thailand)

^h Seoul National University Bundang Hospital   (South Korea)

ⁱ UNIVERSITY OF MEDICINE AND PHARMACY AT HO CHI MINH CITY   (Viet Nam)

^j TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^k MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

more..

Author keywords

Asia; Diabetes; Guidelines; Kidney; Management; Nephropathy; Renal

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BIGUANIDE DERIVATIVE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

ADD ON THERAPY; ASIA; ASIAN; BODY WEIGHT; CARDIOVASCULAR DISEASE; CLINICAL EVALUATION; COMORBIDITY; CREATININE CLEARANCE; DELAYED DIAGNOSIS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EPIDEMIC; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEALTH CARE ACCESS; HEALTH CARE NEED; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MACROALBUMINURIA; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PREVALENCE; RENAL PROTECTION; REVIEW; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN;

ADULT; AGED; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OBESITY; RISK FACTORS;

EID: 84856335635     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.09.023     Document Type: Review

References (99)

1. International Diabetes Federation Diabetes Atlas 2009, International Diabetes Federation, Brussels, Belgium, Accessed on 28.01.11 at. http://www.diabetesatlas.org/content/diabetes, 4th ed.
2. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:4-14.
3. Heine R.J., Diamant M., Mbanya J.-C., Nathan D.M. Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?. BMJ 2006, 333:1200-1204.
4. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
5. Chan J.C., Malik V., Jia W., Kadowaki T., Yajnik C.S., Yoon K.H., et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009, 301:2129-2140.
6. Gu D., Reynolds K., Duan X., Xin X., Chen J., Wu X., et al. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Diabetologia 2003, 46:1190-1198.
7. Jia W.P., Pang C., Chen L., Bao Y.Q., Lu J.X., Lu H.J., et al. Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a cross-sectional 3-year follow-up study in Shanghai urban communities. Diabetologia 2007, 50:286-292.
8. Yang W., Lu J., Weng J., Jia W., Ji L., Xiao J., et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010, 362:1090-1101.
9. Wong K.C., Wang Z. Prevalence of type 2 diabetes mellitus of Chinese populations in Mainland China, Hong Kong, and Taiwan. Diabetes Res Clin Pract 2006, 73:126-134.
10. Ramachandran A. Epidemiology of diabetes in India-three decades of research. J Assoc Physicians India 2005, 53:34-38.
11. Ramachandran A., Mary S., Yamuna A., Murugesan N., Snehalatha C. High prevalence of diabetes and cardiovascular risk factors associated with urbanization in India. Diabetes Care 2008, 31:893-898.
12. Lee W.R. The changing demography of diabetes mellitus in Singapore. Diabetes Res Clin Pract 2000, 50(Suppl 2):S35-S39.
13. Yoon K.H., Lee J.H., Kim J.W., Cho J.H., Choi Y.H., Ko S.H., et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006, 368:1681-1688.
14. Chang C.H., Shau W.Y., Jiang Y.D., Li H.Y., Chang T.J., Sheu W.H., et al. Type 2 diabetes prevalence and incidence among adults in Taiwan during 1999-2004: a national health insurance data set study. Diabet Med 2010, 27:636-643.
15. Hollander P.A., Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med 2010, 122:71-80.
16. Morrish N.J., Wang S.L., Stevens L.K., Fuller J.H., Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Diseases in Diabetes. Diabetologia 2001, 44(Suppl 2):S14-S21.
17. Woodward M., Zhang X., Barzi F., Pan W., Ueshima H., Rodgers A., et al. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care 2003, 26:360-366.
18. Lee C.M., Huxley R.R., Lam T.H., Martiniuk A.L., Ueshema H., Pan W.H., et al. Prevalence of diabetes mellitus and population attributable fractions for coronary heart disease and stroke mortality in the WHO South-East Asia and Western Pacific regions. Asia Pac J Clin Nutr 2007, 16:187-192.
19. Karter A.J., Ferrara A., Liu J.Y., Moffet H.H., Ackerson L.M., Selby J.V. Ethnic disparities in diabetic complications in an insured population. JAMA 2002, 287:2519-2527.
20. Parving H.H., Lewis J.B., Ravid M., Remuzzi G., Hunsicker L.G. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006, 69:2057-2063. DEMAND investigators.
21. Pan C.Y., Ho L.T., Soegondo S., Prodjosudjadi W., Suwanwalaikorn S., Lim S.C., et al. Prevalence of albuminuria and cardiovascular risk profile in a referred cohort of patients with type 2 diabetes: an Asian perspective. Diabetes Technol Ther 2008, 10:397-403.
22. Chang C., Lu F., Yang Y.C., Wu J.S., Wu T.J., Chen M.S., et al. Epidemiologic study of type 2 diabetes in Taiwan. Diabetes Res Clin Pract 2000, 50(Suppl 2):S49-S59.
23. Ngarmukos C., Bunnag P., Kosachunhanun N., Krittiyawong S., Leelawatana R., Prathipanawatr T., et al. Thailand diabetes registry project: prevalence, characteristics and treatment of patients with diabetic nephropathy. J Med Assoc Thai 2006, 89(Suppl 1):S37-S42.
24. Rawdaree P., Ngarmukos C., Deerochanawong C., Suwanwalaikorn S., Chetthakul T., Krittiyawong S., et al. Thailand diabetes registry (TDR) project: clinical status and long-term vascular complications in diabetic patients. J Med Assoc Thai 2006, 89(Suppl 1):S1-S9.
25. Mohan V., Sandeep S., Deepa R., Shah B., Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res 2007, 125:217-230.
26. Yokoyama H., Sone H., Oishi M., Kawai K., Fukumoto Y., Kobayashi M. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management Study (JDDM15). Nephrol Dial Transplant 2009, 24:1212-1219.
27. So W.Y., Kong A.P., Ma R.C., Ozaki R., Szeto C.C., Chan N.N., et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care 2006, 29:2046-2052.
28. Yokoyama H., Okudaira M., Otani T., Watanabe C., Takaike H., Miuira J., et al. High incidence of diabetic nephropathy in early onset Japanese NIDDM patients: risk analysis. Diabetes Care 1998, 21:1080-1085.
29. Liu W.J., Hooi L.S. Patients with end stage renal disease: a registry at Sultanah Aminah Hospital, Johor Bahru, Malaysia. Med J Malaysia 2007, 62:197-200.
30. Friberg E., Orsini N., Mantzoros C.S., Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 2007, 50:1365-1374.
31. Huxley R., Ansary-Moghaddam A., Berrington de González A., Barzi F., Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005, 92:2076-2083.
32. El-Serag H.B., Hampel H., Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006, 4:369-380.
33. Larsson S.C., Orsini N., Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005, 97:1679-1687.
34. Chan J.C., Cheung C.K., Cheung M.Y., Swaminathan R., Critchley J.A., Cockram C.S. Abnormal albuminuria as a predictor of mortality and renal impairment in Chinese patients with NIDDM. Diabetes Care 1995, 18:1013-1016.
35. Yang X., So W.Y., Kong A.P., Ma R.C., Ko G.T., Ho C.S., et al. Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am J Cardiol 2008, 101:596-601.
36. Yang X., So W.Y., Ma R.C., Kong A.P., Lee H.M., Yu L.W., et al. Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 2011, 34:375-380.
37. American Diabetes Association Standards of Medical Care in Diabetes-2011. Diabetes Care 2011, 34(Suppl 1):S11-S61.
38. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009, 52:17-30.
39. International Diabetes Federation Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes 2005, International Diabetes Federation, Brussels, Accessed 25.01.11 at:. http://www.idf.org/webdata/docs/IDF%2520GGT2D.pdf.
40. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
41. Lindström J., Louheranta A., Mannelin M., Rastas M., Salminen V., Eriksson J., et al. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003, 26:3230-3236.
42. Wenying Y., Lixiang L., Jinwu Q., Guangwei L., Zhiqing Y., Xiaoren P. The preventive effect of acarbose and metformin on the IGT population from becoming diabetes mellitus: a 3-year multicentral prospective study. Chin J Endocrinol Metab 2001, 17:131-134.
43. Pan X.R., Li G.W., Hu Y.H., Wang J.X., Yang W.Y., An Z.X., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20:537-544.
44. Ramachandran A., Snehalatha C., Mary S., Mukesh B., Bhaskar A.D., Vijay V., et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006, 49:289-297.
45. Knowler W.C., Fowler S.E., Hamman R.F., Christophi C.A., Hoffman H.J., et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686. Diabetes Prevention Program Research Group.
46. Herman W.H., Edelstein S.L., Ratner R.E., Montez M.G., Ackermann R.T., Orchard T.J., et al. The 10-Year cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes mellitus: an intent-to-treat analysis of diabetes prevention,. Late-breaking Oral Presentation at American Diabetes Association 71st Annual Scientific Sessions 2011, Accessed on 3.8.11 at. http://www2.aievolution.com/ada1101/index.cfm%3Fdo=abs.viewAbs%26abs=12714.
47. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281:2005-2012.
48. Yu N.C., Su H.Y., Tsai S.T., Lin B.J., Shiu R.S., Hsieh Y.C., et al. ABC control of diabetes: survey data from National Diabetes Health Promotion Centers in Taiwan. Diabetes Res Clin Pract 2009, 84:194-200.
49. Adler A.I., Shaw E.J., Stokes T., Ruiz F. Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance. BMJ 2009, 338:b1668. Guideline Development Group.
50. Rodbard H.W., Jellinger P.S., Davidson J.A., Einhorn D., Garber A.J., Grunberger G., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15:540-549.
51. Stults B., Jones R.E. Management of hypertension in diabetes. Diabetes Spect 2006, 19:25-31.
52. Barnett A.H., Bain S.C., Bouter P., Karlberg B., Madsbad S., Jervell J., et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004, 351:1952-1961.
53. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final Report. Bethesda, Md: National Heart, Lung, and Blood Institute; 2002. Accessed 18/04/2011 at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf.
54. Snow V., Aronson M.D., Hornbake E.R., Mottur-Pilson C., Weiss K.B. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004, 140:469-644. Clinical Efficacy Assessment Subcommittee of the American College of Physicians.
55. American Diabetes Association Dyslipidemia management in adults with diabetes. Diabetes Care 2004, 27(Suppl 1):S68-S70.
56. Blackburn G.L. Effect of degree of weight loss on health benefits. Obes Res 1995, 3:S211S-S216S.
57. Knowler C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
58. Davidson M.B., Peters A.L. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997, 102:99-110.
59. Delea T.E., Edelsberg J.S., Hagiwara M., Oster G., Phillips L.S. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003, 26:2983-2989.
60. Baskin S., Neher J.O., Dodson S., Hoffman R. Clinical inquiries. Do TZDs increase the risk of heart failure for patients with diabetes?. J Fam Pract 2005, 54:723-724.
61. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 2(Suppl 1):S1-S266.
62. Kunz R., Bork J.P., Fritsche L., Ringel J., Sharma A.M. Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: a methodologic appraisal and systematic review. J Am Soc Nephrol 1998, 9:1653-1663.
63. Chandie Shaw P.K., Baboe F., van Es L.A., van der Vijver J.C., van de Ree M.A., de Jonge N., et al. South-Asian type 2 diabetic patients have higher incidence and faster progression of renal disease compared with Dutch-European diabetic patients. Diabetes Care 2006, 29:1383-1385.
64. Ninomiya T., Perkovic V., de Galan B.E., Zoungas S., Pillai A., Jardine M., et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009, 20:1813-1821.
65. Katakura M., Naka M., Kondo T., Komatsu M., Yamauchi K., Hashizume K., et al. Normal mortality in the elderly with diabetes under strict glycemic and blood pressure control: outcome of 6-year prospective study. Diabetes Res Clin Pract 2007, 78:108-114.
66. Wu M.C., Lee W.J., Tschen S.M., Lin S.Y., Lee I.T., Jeng C.Y., et al. Predictors of mortality in hospitalized diabetic patients: a 7-year prospective study. Diabetes Res Clin Pract 2008, 80:449-454.
67. de Zeeuw D., Ramjit D., Zhang Z., Ribeiro A.B., Kurokawa K., Lash J., et al. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. Kidney Int 2006, 69:1675-1682.
68. Satko S.G., Freedman B.I., Moossavi S. Genetic factors in end-stage renal disease. Kidney Int 2005, 94(Suppl):S46-S49.
69. Bo S., Cavallo-Perin P., Gentile L., Repetti E., Pagano G. Hypouricemia and hyperuricemia in type 2 diabetes: two different phenotypes. Eur J Clin Invest 2001, 31:318-321.
70. Tseng C.H. Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. Kidney Int 2005, 68:796-801.
71. Singh N.P., Ingle G.K., Saini V.K., Jami A., Beniwal P., Lal M., et al. Prevalence of low glomerular filtration rate, proteinuria and associated risk factors in North India using Cockcroft-Gault and modification of diet in renal disease equation: an observational, cross-sectional study. BMC Nephrol 2009, 10:4.
72. Pedro R.A., Ramon S.A., Marc B.B., Juan F.B., Isabel M.M. Prevalence and relationship between diabetic retinopathy and nephropathy, and its risk factors in the North-East of Spain, a population-based study. Ophthalmic Epidemiol 2010, 17:251-265.
73. Lin Y.Y., Hsu C.W., Sheu W.H., Chu S.J., Wu C.P., Tsai S.H. Risk factors for recurrent hypoglycemia in hospitalized diabetic patients admitted for severe hypoglycemia. Yonsei Med J 2010, 51:367-374.
74. Fong D.S., Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol 2009, 147:583-586.
75. Kidney Disease Outcomes Quality Initiative Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007, 49(Suppl 2):S12-S154.
76. Nauck M.A., Vilsbøll T., Gallwitz B., Garber A., Madsbad S. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009, 32(Suppl 2):S223-S231.
77. Richter B., Bandeira-Echtler E., Bergerhoff K., Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008, 4:753-768.
78. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
79. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
80. Saxena A., Fish J.E., White M.D., Yu S., Smyth J.W., Shaw R.M., et al. Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction. Circulation 2008, 117:2224-2231.
81. Cavusoglu E., Eng C., Chopra V., Clark L.T., Pinsky D.J., Marmur J.D. Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography. Arterioscler Thromb Vasc Biol 2007, 27:929-935.
82. Iwamoto Y., Nonaka K., Okada A., Okuyama K., Stein P.P. Dose-response relationship for glycemic efficacy, safety and tolerability of sitagliptin after 12 weeks of treatment in Japanese patients with type 2 diabetes mellitus. Diabetologia 2007, 50(Suppl 1):S366. [Abstract PS888].
83. Mohan V., Yang W., Son H.Y., Xu L., Noble L., Langdon R.B., et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India and Korea. Diabetes Res Clin Pract 2009, 83:106-116.
84. Chan J.C., Scott R., Arjona Ferreira J.C., Sheng D., Gonzalez E., Davies M.J., et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008, 10:545-555.
85. Aschner P., Kipnes M.S., Lunceford J.K., Sanchez M., Mickel C., Williams-Herman D.E., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29:2632-2637.
86. Raz I., Hanefeld M., Xu L., Caria C., Williams-Herman D., Khatami H., et al. Efficacy and safety of dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006, 49:2564-2571.
87. Pi-Sunyer F.X., Schweizer A., Mills D., Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract 2007, 76:132-138.
88. Kikuchi M., Abe N., Kato M., Terao S., Mimori N., Tachibana H. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2009, 83:233-240.
89. Charbonnel B., Karasik A., Liu J., Wu M., Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29:2638-2643. Sitagliptin Study 020 Group.
90. Schweizer A., Couturier A., Foley J.E., Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabet Med 2007, 24:955-961.
91. Pan C., Yang W., Barona J.P., Wang Y., Niggli M., Mohideen P., et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008, 25:435-441.
92. Kikuchi M., Haneda M., Koya D., Tobe K., Onishi Y., Couturier A., et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus. Diabetes Res Clin Pract 2010, 89:216-223.
93. Louisa M., Takeuchi M., Takeuchi M., Nafrialdi M., Setiabudy R. Incretin-based therapies for type 2 diabetes mellitus in Asian patients: analysis of clinical trials. Med J Indones 2010, 19:205-212.
94. Patel D.S., Mehta H.R., Ramani A.K., Labana P.G., Shah S.K., Srivstava A.K., et al. Liraglutide: a molecule for treatment of type II diabetes mellitus. Res J Pharm Biol Chem Sci 2010, 1:193-201.
95. Seino Y., Rasmussen M.F., Nishida T., Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 2010, 26:1013-1022.
96. Kim S.W. Triple combination therapy using metformin, thiazolidinedione, and a GLP-1 analog or DPP-IV inhibitor in patients with Type 2 diabetes mellitus. Korean Diab J 2010, 34:331-337.
97. United States Food and Drug Administration. Highlights of prescribing information. Januvia® (sitagliptin) tablets. Initial U.S. Approval: 2006. Accessed on 12.05.2011 at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021995s013lbl.pdf.
98. United States Food and Drug Administration. Highlights of prescribing information. Tradjenta™ (linagliptin) tablets. Initial U.S. Approval: 2011. Accessed on 10.05.2011 at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201280lbl.pdf.
99. Trajenta™ (linagliptin) tablets. EMA Summary of Product Characteristics, 2011.